US FDA Grants Orphan Drug Designation to Enzychem Lifesciences Treatment for Acute Radiation Syndrome.
M2 PHARMA-January 26, 2018-US FDA Grants Orphan Drug Designation to Enzychem Lifesciences Treatment for Acute Radiation Syndrome
(C)2018 M2 COMMUNICATIONS
- Seoul, South Korea-based biopharmaceutical company Enzychem Lifesciences, Corp. (KONEX: 183490) has been granted Orphan Drug Designation by the US Food and Drug Administration for EC-18 for the treatment of acute radiation syndrome, the company said.
Caused by a critical exposure to radiation, acute radiation syndrome includes neutropenia, nervous system damage, and pneumonia with high fatality rate.
EC-18 is a small molecule compound designed for oral administration that could have a role in treating immune and inflammatory related diseases, including psoriasis, rheumatoid arthritis, asthma, atopic dermatitis, and sepsis.
Enzychem Lifesciences is conducting phase II clinical trials on indications of chemotherapy-induced neutropenia and chemo-radiotherapy induced oral mucositis in the United States.
Enzychem Lifesciences is a global new drug development company with an R and D driven approach. The company is developing innovative treatments which can address significant unmet medical needs.
((Comments on this story may be sent to email@example.com))
|Printer friendly Cite/link Email Feedback|
|Date:||Jan 26, 2018|
|Previous Article:||Alligator Bioscience names Theradex Oncology as clinical CRO for the upcoming ATOR-1015 phase I study.|
|Next Article:||UPM Pharmaceuticals Promotes Curtin to COO.|